Chemomab Therapeutics

Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases

Health Tech & Life Sciences
Public on NASDAQ on Mar, 2021<br>

Company Overview

Snapshot

Founded in November 2011 by Adi Mor, Chemomab Therapeutics operates with 11–50 employees. The company has raised a total of $90.5M across 7 funding rounds from 12 investors. In March 2021, Chemomab Therapeutics completed a reverse merger with Anchiano Therapeutics, leading to its public listing on NASDAQ.

Business overview

Chemomab Therapeutics is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's core technology revolves around CM-101, a first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24, which plays a pivotal role in promoting fibrosis and inflammation. Chemomab serves the healthcare and life sciences market, specifically targeting patients with severe and life-threatening fibro-inflammatory conditions, operating within the pharmaceuticals and medical biotechnology sectors.

Strategic signal

In May 2024, Chemomab Therapeutics was granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. This indicates a period of strategic focus for the company to address its stock performance and maintain its listing, signaling to investors the immediate need for operational and financial adjustments to meet market expectations.

Company Intelligence Q&A

What is Chemomab Therapeutics' primary focus?
Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs.
When did Chemomab Therapeutics become a public company?
Chemomab Therapeutics became public on NASDAQ in March 2021, following a reverse merger with Anchiano Therapeutics.
What is CM-101?
CM-101 is Chemomab Therapeutics' first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24, which is central to promoting fibrosis and inflammation.
What was a significant regulatory development for CM-101 in late 2023?
In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis.
What recent action did Nasdaq take regarding Chemomab Therapeutics' listing?
In May 2024, Chemomab Therapeutics was granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule.

External links